AIM ImmunoTech secures patent in Japan through 2039 for therapy using Ampligen

AIM ImmunoTech (AIM) announced that the Japan Patent Office has issued a patent covering the Company’s proprietary use of Ampligen in combination with checkpoint inhibitors for the treatment of cancer. “We remain committed to strengthening our global intellectual property protection for Ampligen as we continue to advance its clinical development. This Japan patent – which does not expire until December 20, 2039 – further strengthens our intellectual property portfolio in one of the world’s largest oncology markets and enhances exclusivity around combination therapies that address high-need cancer indications. Importantly, this patent further reinforces our ability to advance our clinical pipeline, secure strategic collaborations, and capture value in the growing global immuno-oncology sector. The scope of this patent enhances the value for any future strategic oncology transactions,” AIM ImmunoTech CEO Thomas K. Equels stated.